睾丸癌核蛋白的多组学特征和分子谱分析

IF 5.3 2区 医学 Q1 ONCOLOGY
JCO precision oncology Pub Date : 2024-10-01 Epub Date: 2024-10-24 DOI:10.1200/PO.24.00334
Gianna Kroening, Jia Luo, Mark G Evans, Tolulope Adeyelu, Sai-Hong Ignatius Ou, Zhaohui L Arter, Trisha M Wise-Draper, Ammar Sukari, Asfar S Azmi, David R Braxton, Andrew Elliott, David A Bryant, Matthew J Oberley, Chul Kim, Geoffrey I Shapiro, Christopher A French, Misako Nagasaka
{"title":"睾丸癌核蛋白的多组学特征和分子谱分析","authors":"Gianna Kroening, Jia Luo, Mark G Evans, Tolulope Adeyelu, Sai-Hong Ignatius Ou, Zhaohui L Arter, Trisha M Wise-Draper, Ammar Sukari, Asfar S Azmi, David R Braxton, Andrew Elliott, David A Bryant, Matthew J Oberley, Chul Kim, Geoffrey I Shapiro, Christopher A French, Misako Nagasaka","doi":"10.1200/PO.24.00334","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene <i>NUTM1</i> on chromosome 15q14. Co-occurring alternations have not been fully characterized.</p><p><strong>Methods: </strong>We analyzed the genomic and immune landscape of 54 cases of NC that underwent DNA- and RNA-based NGS sequencing (Caris).</p><p><strong>Results: </strong>While NC is driven by <i>NUTM1</i> fusion oncoproteins, co-occurring DNA mutations in epigenetic or cell cycle pathways were observed in 26% of cases. There was no significant difference between the fusion partner of <i>NUTM1</i> and co-occurring gene mutations. RNA sequencing analysis showed increased <i>MYC</i> pathway activity in NC compared with head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC), which is consistent with the known pathophysiology of NC. Characterization of the NC tumor microenvironment using RNA sequencing revealed significantly lower immune cell infiltration compared with HNSCC and LUSC. NC was 10× higher in patients with HNSCC and LUSC younger than 50 years than in those older than 70 years.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first series of NC profiled broadly at the DNA and RNA level. We observed fewer intratumoral immune cells by RNA sequencing, which may be associated with anecdotal data of lack of immunotherapy benefit in NC. High <i>MYC</i> pathway activity in NC supports ongoing trials targeting <i>MYC</i> suppression. The incidence of NC among patients younger than 50 years with LUSC/HNSCC supports testing for NC in these patients. The prognosis of NCs remains dismal, and future studies should focus on improving the response to immunotherapy and targeting MYC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"8 ","pages":"e2400334"},"PeriodicalIF":5.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520346/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma.\",\"authors\":\"Gianna Kroening, Jia Luo, Mark G Evans, Tolulope Adeyelu, Sai-Hong Ignatius Ou, Zhaohui L Arter, Trisha M Wise-Draper, Ammar Sukari, Asfar S Azmi, David R Braxton, Andrew Elliott, David A Bryant, Matthew J Oberley, Chul Kim, Geoffrey I Shapiro, Christopher A French, Misako Nagasaka\",\"doi\":\"10.1200/PO.24.00334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene <i>NUTM1</i> on chromosome 15q14. Co-occurring alternations have not been fully characterized.</p><p><strong>Methods: </strong>We analyzed the genomic and immune landscape of 54 cases of NC that underwent DNA- and RNA-based NGS sequencing (Caris).</p><p><strong>Results: </strong>While NC is driven by <i>NUTM1</i> fusion oncoproteins, co-occurring DNA mutations in epigenetic or cell cycle pathways were observed in 26% of cases. There was no significant difference between the fusion partner of <i>NUTM1</i> and co-occurring gene mutations. RNA sequencing analysis showed increased <i>MYC</i> pathway activity in NC compared with head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC), which is consistent with the known pathophysiology of NC. Characterization of the NC tumor microenvironment using RNA sequencing revealed significantly lower immune cell infiltration compared with HNSCC and LUSC. NC was 10× higher in patients with HNSCC and LUSC younger than 50 years than in those older than 70 years.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first series of NC profiled broadly at the DNA and RNA level. We observed fewer intratumoral immune cells by RNA sequencing, which may be associated with anecdotal data of lack of immunotherapy benefit in NC. High <i>MYC</i> pathway activity in NC supports ongoing trials targeting <i>MYC</i> suppression. The incidence of NC among patients younger than 50 years with LUSC/HNSCC supports testing for NC in these patients. The prognosis of NCs remains dismal, and future studies should focus on improving the response to immunotherapy and targeting MYC.</p>\",\"PeriodicalId\":14797,\"journal\":{\"name\":\"JCO precision oncology\",\"volume\":\"8 \",\"pages\":\"e2400334\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520346/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO precision oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/PO.24.00334\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO.24.00334","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:睾丸癌核蛋白(NC)是一种诊断率低、侵袭性强的鳞状癌/分化差的癌症,其特征是染色体 15q14 上的 NUTM1 基因发生重排。方法:我们分析了基因组和免疫系统:我们分析了 54 例接受 DNA 和 RNA NGS 测序(Caris)的 NC 的基因组和免疫图谱:结果:虽然NC是由NUTM1融合肿瘤蛋白驱动的,但在26%的病例中观察到表观遗传或细胞周期通路中同时存在DNA突变。NUTM1的融合伙伴与共存基因突变之间没有明显差异。RNA测序分析表明,与头颈部鳞状细胞癌(HNSCC)和肺鳞状细胞癌(LUSC)相比,NC的MYC通路活性增加,这与已知的NC病理生理学相一致。利用 RNA 测序分析 NC 肿瘤微环境的特征发现,与 HNSCC 和 LUSC 相比,免疫细胞浸润明显较低。在50岁以下的HNSCC和LUSC患者中,NC的发病率是70岁以上患者的10倍:据我们所知,这是第一例在DNA和RNA水平上对NC进行广泛分析的系列研究。通过RNA测序,我们观察到瘤内免疫细胞较少,这可能与NC缺乏免疫疗法获益的传闻有关。NC中MYC通路的高活性为正在进行的以抑制MYC为目标的试验提供了支持。在 50 岁以下的 LUSC/HNSCC 患者中,NC 的发病率较高,这支持对这些患者进行 NC 检测。NC的预后仍然不容乐观,未来的研究应侧重于改善对免疫疗法和靶向MYC的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma.

Purpose: Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene NUTM1 on chromosome 15q14. Co-occurring alternations have not been fully characterized.

Methods: We analyzed the genomic and immune landscape of 54 cases of NC that underwent DNA- and RNA-based NGS sequencing (Caris).

Results: While NC is driven by NUTM1 fusion oncoproteins, co-occurring DNA mutations in epigenetic or cell cycle pathways were observed in 26% of cases. There was no significant difference between the fusion partner of NUTM1 and co-occurring gene mutations. RNA sequencing analysis showed increased MYC pathway activity in NC compared with head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC), which is consistent with the known pathophysiology of NC. Characterization of the NC tumor microenvironment using RNA sequencing revealed significantly lower immune cell infiltration compared with HNSCC and LUSC. NC was 10× higher in patients with HNSCC and LUSC younger than 50 years than in those older than 70 years.

Conclusion: To our knowledge, this is the first series of NC profiled broadly at the DNA and RNA level. We observed fewer intratumoral immune cells by RNA sequencing, which may be associated with anecdotal data of lack of immunotherapy benefit in NC. High MYC pathway activity in NC supports ongoing trials targeting MYC suppression. The incidence of NC among patients younger than 50 years with LUSC/HNSCC supports testing for NC in these patients. The prognosis of NCs remains dismal, and future studies should focus on improving the response to immunotherapy and targeting MYC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.10
自引率
4.30%
发文量
363
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信